Zydus secures Mexico’s COFEPRIS approval for its biosimilar ‘Bhava’ to treat various cancers

Zydus Lifesciences receives approval to market Bhava™ for various cancers in Mexico, expanding access to affordable oncology treatments

0
41
New Delhi: Zydus Lifesciences Limited has announced that Mexico’s Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) has approved its Bevacizumab biosimilar, Bhava™, for marketing in the country. 
This biosimilar will be available in 100 mg/4 ml and 400 mg/16 ml strengths and is intended for the treatment of several types of cancer, including metastatic Colorectal Cancer (mCRC), non-squamous non-small cell lung cancer, metastatic breast cancer, glioblastoma, advanced and/or metastatic renal cell carcinoma, and ovarian cancer. According to a 2020 WHO report, breast, prostate, colorectal, and thyroid cancers were among the most frequently reported cancer types in Mexico.
Dr. Sharvil Patel, Managing Director of Zydus, expressed, “We welcome the approval granted to the first of our biosimilars for patients in Latin America. To bring greater access and affordability to patients battling critical ailments, we have been developing a pipeline of biosimilars, specifically in oncology. Precision diagnostics and access to affordable therapies are empowering millions of patients in their fight against cancer in India. With BhavaTM, we begin a new journey of supporting patients with need-based therapies in Latin America.”
The Bevacizumab biosimilar was developed in-house by the research team at the Zydus Research Centre (ZRC) and was first launched in India in 2015 under the brand name Bryxta™. Since its introduction, it has been administered to approximately 50,000 patients in India. With Bhava™, Zydus aims to extend its reach and offer cost-effective treatment options to cancer patients in Latin America.
This approval is part of Zydus’s broader strategy to address the unmet needs in oncology through its growing portfolio of lifesaving biosimilars, with twelve such products already launched in the market.